Analytical Data
-
Gene name
C1qB
- Application
-
Alternative Names
Complement Component 1,q Subcomponent,Beta Polypeptide
-
Species
Human
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P02746
-
Expression Region
Gln28~Ala253
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C1qB is a significant component of the complement system, specifically serving as part of the C1 complex, which initiates the classical pathway of complement activation. This pathway plays a crucial role in the immune response by facilitating opsonization, promoting inflammation, and enhancing phagocytosis of pathogens. Given the importance of C1qB in immune regulation, researchers have focused on the structure, function, and mechanisms of this protein. Studies have shown that alterations in C1qB expression or function can be linked to various autoimmune diseases and infectious responses. Recombinant C1qB proteins are being developed for use in both diagnostic and therapeutic applications, allowing for a better understanding of complement-mediated processes and potential treatments for complement-related disorders. The ability to produce C1qB in a recombinant form provides an essential tool for dissecting its role in immune system function and for developing new strategies for modulating its activity in disease contexts. Furthermore, the structural insights gained from studying recombinant C1qB can inform the design of novel therapeutic agents that target specific aspects of the complement pathway, enhancing our capacity to treat immune disorders effectively. Overall, the research surrounding recombinant C1qB is paving the way for innovative approaches in immunology and therapeutic interventions.
